ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Avasopasem manganese (Primary)
- Indications Stomatitis
- Focus Registrational; Therapeutic Use
- Acronyms ROMAN
- Sponsors Galera Therapeutics
- 08 Oct 2019 According to a Galera Therapeutics media release, topline data anticipated in the first half of 2021.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 16 Oct 2018 According to a Galera Therapeutics media release, data of this trial will support the submission of a New Drug Application of GC-4419 to the U.S. Food and Drug Administration